Daraxonrasib for pancreatic cancer already offered at Mass General Brigham
Louis reports that Mass General Brigham is treating pancreatic cancer patients with daraxonrasib through the FDA Expanded Access Program ahead of approval, and suggests other large hospitals may do the same. Coverage describes it as a historic pill that could double life expectancy in advanced disease.